Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hepatitis C 1

Interventions

Cyclophosphamide 17Rituximab 12Prednisone 7Peripheral Blood Stem Cell Transplantation 7Filgrastim 7sargramostim 6Vincristine 6fludarabine phosphate 5Radiotherapy 5Doxorubicin 5Cytarabine 5Cisplatin 5ibritumomab tiuxetan 4Methylprednisolone 4Melphalan 4Etoposide 4Dexamethasone 4Cyclosporine 4epratuzumab 3Sensitivity and Specificity 3Polymerase Chain Reaction 3Mycophenolic Acid 3Indium 3Chlorambucil 3Busulfan 3Bendamustine Hydrochloride 3Antilymphocyte Serum 3Antigens, CD19 3obinutuzumab 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Follicular × ledipasvir, sofosbuvir drug combination × Clear all
NCT03261349 2017-08-25

Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma

National Taiwan University Hospital

Phase 2 Unknown
21 enrolled
Lymphoid

Hepatitis C, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡